Pembrolizumab more value in squamous cell carcinomas or adenocarcinomas ASCO GI 2016

Dr. Toshihiko Doi, MD of National Cancer Center Hospital East, Japan discusses pembrolizumab and more value in squamous cell carcinomas or adenocarcinomas ASCO GI 2016 Author: ASCOGI2016 Added: 01/29/2016
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts